Aims
AMPD1 c.34C > T (rs17602729) polymorphism
Conclusion
AMPD1 deficiency may be involved in the modulation of regadenoson's systemic effects.
Methods
Genotyping for c.34C>T was performed in 267 patients undergoing regadenoson cardiac stress testing.
Results
Carriers of c.34C >T variant exhibited higher relative changes in systolic blood pressure (SBP) compared with wild-type subjects ([%] SBP change to peak: 12 ± 25 vs 5 ± 13%; p = 0.01) ([%] SBP change to nadir: -3 ± 15 vs -7 ± 11%; p = 0.04). Change in heart rate was similar between groups, but side effects were more common in carriers of the variant (+LR = 4.2; p = 0.04).